Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207709 · ClinicalTrials.gov registry record · Phase 3
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
A Phase 3 study of Metastatic Breast Cancer, sponsored by SOLTI Breast Cancer Research Group.
- Active
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
- 20
- Study locations
NCT05207709 is a Phase 3 study of Metastatic Breast Cancer that is active but no longer recruiting, run by SOLTI Breast Cancer Research Group. The registered enrollment target is 456 participants, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05207709, a Phase 3 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by SOLTI Breast Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
- 20
- Study locations
Study Summary
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 sites worldwide. In addition, the HARMONIA trial will include an exploratory cohort of patients with HR+/HER2- and Basal-like disease treated with paclitaxel +/- Tislelizumab. This cohort does not have a predefined sample size and the objective is only exploratory, given the suggested lack of efficacy of the combinations of hormone therapy and CDK4/6 inhibitors in this subgroup of patients. Enrolment into the basal-like cohort will stop once the HER2-E disease cohort is fully enrolled.
Conditions Studied
Interventions
- DRUG Ribociclib + Letrozole OR Fulvestrant
- DRUG Palbociclib + Letrozole OR Fulvestrant
- DRUG Paclitaxel +/- Tislelizumab
Study Locations (20)
Florida
- Morton Plant Hospital - Clearwater
- University of Miami - Coral Gables
- Memorial Regional Hospital - Hollywood
- Mount Sinai Florida - Miami
Illinois
- Northwestern - Chicago
- Carle Cancer Center - Urbana
New York
- Nothwell Health - New York
- Montefiore - The Bronx
North Carolina
- University of North Carolina Lineberger - Chapel Hill
- Novant Health Care - Winston-Salem
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
- Dayton Clinical Oncology - Kettering
Kentucky
- University of Kentucky, Markey Cancer Center - Lexington
Maryland
- Sinai of Baltimore - Baltimore
Massachusetts
- Dana Faber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05207709
The ClinicalTrials.gov registry entry for NCT05207709 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (126% higher). The listed sponsor is SOLTI Breast Cancer Research Group, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Ribociclib + Letrozole OR Fulvestrant is the first listed.
NCT05207709 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05207709 about?
NCT05207709 is a clinical study titled "Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype". HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestran...
What is the current status of trial NCT05207709?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2022-03-28. Estimated completion is 2027-03-01.
What conditions does trial NCT05207709 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05207709?
The interventions under investigation include: Ribociclib + Letrozole OR Fulvestrant (DRUG), Palbociclib + Letrozole OR Fulvestrant (DRUG), Paclitaxel +/- Tislelizumab (DRUG).
Who is sponsoring clinical trial NCT05207709?
This trial is sponsored by SOLTI Breast Cancer Research Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05207709 being conducted?
This trial has 20 study locations across Florida, Illinois, Kentucky, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RECRUITING · Phase 3
-
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
RECRUITING · Phase 3
-
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
-
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 3
-
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.